Skip to main content
search

Value & Access Services

Follow the most promising path to commercial success

Learn more

Proven payer strategies and scientific excellence

Certara’s Value & Access Services empower biotech and pharmaceutical innovators to effectively define and communicate the value of their therapies. Through a unique marriage of analytics on data in real-world settings and proven payer strategies, our team specializes in how to best leverage evidence for pricing, market access, and reimbursement success.

Integrated toolset

Strategists take a multi-disciplinary approach that combines decades of experience in payer value demonstration with unparalleled scientific excellence.

Focus on real world impact

Value demonstration and evidence generation are drive by your product’s real world impact, not its clinical trial results

Conception to submission

A streamlined process at every step of drug development for optimal access

Senior leadership commitment

Daily, hands-on participation in all customer engagements

Our expert scientific engagement and submission offerings

Systematic literature reviews

Ad hoc/targeted evidence synthesis

Core and global value dossiers

AMCP dossiers

Value frameworks

ICER value assessments

Local HTA reimbursement submissions

Joint clinical assessment (JCA) submissions

Our Value & Access services leaders

Roman Casciano, PhD, MEng
1 / 3
Experts

Roman Casciano, PhD, MEng

SVP, Evidence & Access

As an applied health economist and market access strategist, Roman has personally led hundreds of engagements in the global market access, HEOR and real-world evidence context related to product value demonstration and has deep experience in both formal and informal exchanges with payers and HTA bodies.

 

Maximilian Vargas, PhD, MBA
2 / 3
Experts

Maximilian Vargas, PhD, MBA

Vice President, US Access Strategy

Maximilian Vargas, PhD MBA, is a Vice President, US Access Strategy within Certara’s Evidence and Access Group since 2012. He brings both scientific training and experience in healthcare product development that are important for evidence-based value and access strategies for pipeline and marketed products.

Elvira Müller, PhD, MPH
3 / 3
Experts

Elvira Müller, PhD, MPH

VP, HTA Strategy and Access

Elvira is responsible for HTA and Evidence Development while managing Certara’s consulting team based in Germany. Besides numerous HTA engagements, she has substantial expertise in EUnetHTA collaboration as well as in European Joint Clinical Assessments (JCA) and Joint Scientific Consultation (JSC). She has 20+ years of experience in global m...

Partner with Certara for evidence-based success

Certara’s Value & Access team offers customers an integrated toolbox that combines decades of experience in payer value demonstration and access strategy with unparalleled scientific excellence in real world evidence, health economics, advanced analytics and evidence synthesis.

Deepen your knowledge with these resources

View all
1 / 3
Brochure

Evidence and Access Overview

Discover Certara’s holistic approach to market access.
Read more
2 / 3
Case Study

Defining path-to-market strategy through a data-driven and scientific approach

How Certara supported a gene therapy manufacturer by using a selection of gateway and value indications as the foundation for the next phase of clinical development.
Read more
3 / 3
White Paper

Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement  

White paper exploring the IRA’s small but measurable impact in several key areas
Read more

Ready to Optimize Your Value & Access Strategy?

Connect with Certara’s experts to learn how we can help you navigate the complexities of health economics and market access. With our combination of payer strategies and scientific excellence services, your therapy is positioned for success.

Proven combination of real-world data insights and proven payer strategies
Unmatched knowledge of local reimbursement requirements and regulations
Leader in health economic modeling and decision analytics


Explore related products and services

Discover Certara's comprehensive Real-World Evidence Services. We provide innovative RWE solutions for pharma, empowering regulatory, market access, and clinical strategies.

Read more

With 25+ years of HEOR consulting expertise, we offer HTA health economic analyses, clinical trial analytics for HTA applications, epidemiology models, and more.

Read more

Certara’s Market Access & Commercial solutions provide strategic insights and tools to optimize pricing, reimbursement, and market entry strategies.

Read more

Market Access Radar delivers up-to-date pricing and reimbursement data from global sources, helping you navigate market access challenges with confidence.

Read more

FAQs

What is a Value Strategy in the pharmaceutical industry?

Value Strategy refers to demonstrating the clinical and economic value of a therapy to secure market access and reimbursement.

How does Certara assist with ICER reviews?

We provide evidence-based modeling and holistic strategies to align with ICER frameworks and identify evidence gaps.

What is a Global Value Dossier (GVD)?

A GVD is a comprehensive compilation of evidence and data supporting the value of a therapy, tailored to HTA standards.